首页> 外文期刊>Bulletin of the Korean Chemical Society >An Improved Convergent Approach for Synthesis of Erlotinib, a Tyrosine Kinase Inhibitor, via a Ring Closure Reaction of Phenyl Benzamidine Intermediate
【24h】

An Improved Convergent Approach for Synthesis of Erlotinib, a Tyrosine Kinase Inhibitor, via a Ring Closure Reaction of Phenyl Benzamidine Intermediate

机译:通过苯甲am中间体的闭环反应合成酪氨酸激酶抑制剂厄洛替尼的改进的收敛方法

获取原文
获取外文期刊封面目录资料

摘要

An improved convergent and economical method has been developed for the synthesis of erlotinib, a 4-anilinoquinazoline and an EGFR-tyrosine kinase inhibitor for treatment of non-small-cell lung cancer. The final two steps for the formation of this 4-anilinoquinazoline from suitable 2-aminobenzonitrile intermediate and 3-ethynylaniline were modified and were performed in a simple one-pot reaction. The ring-closing mechanism for the formation of erlotinib from the suitable formamidine intermediate and 3-ethynylaniline was investigated and determined to proceed via the formation of phenyl benzamidine intermediate rather than involving Dimroth rearrangement reported earlier. The new benzamidine intermediate was isolated for the first time and characterized.
机译:已开发出一种改进的收敛且经济的方法,用于合成埃洛替尼,4-苯胺基喹唑啉和EGFR-酪氨酸激酶抑制剂,用于治疗非小细胞肺癌。由合适的2-氨基苄腈中间体和3-乙炔基苯胺形成4-苯胺基喹唑啉的最后两个步骤进行了修饰,并在简单的一锅反应中进行。研究了从合适的甲am中间体和3-乙炔基苯胺形成埃洛替尼的闭环机理,并确定其是通过形成苯基苄am中间体而进行的,而不是先前报道的Dimroth重排。首次分离出新的苄am中间体并进行了表征。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号